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Abstract 
Breast cancer is known to be a hormone-dependent disease, and estrogens 
through an interaction with estrogen receptor (ER) enhance the proliferative and 
metastatic activity of breast tumor cells.  Here we show a critical role of 
transactivation of BIG3, brefeldin A-inhibited guanine nucleotide-exchange 
protein 3, in activation of the estrogen/ER signaling in breast cancer cells.  
Knocking-down of BIG3 expression with small-interfering RNA (siRNA) 
drastically suppressed the growth of breast cancer cells.  Subsequent 
co-immunoprecipitation and immunoblotting assays revealed an interaction of 
BIG3 with prohibitin 2/repressor of estrogen receptor activity (PHB2/REA).  
When BIG3 was absent, stimulation of estradiol caused the translocation of 
PHB2/REA to the nucleus, enhanced the interaction of PHB2/REA and ERα, and 
resulted in suppression of the ERα transcriptional activity.  On the other hand, 
when BIG3 was present, BIG3 trapped PHB2/REA in cytoplasm and inhibited its 
nuclear translocation, and caused enhancement of ERα transcriptional activity.  
Our results imply that BIG3 overexpression is one of the important mechanisms 
causing the activation of the estrogen/ERα signaling pathway in the 
hormone-related growth of breast cancer cells. 
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Introduction 
Breast cancer is the most common cancer among women worldwide; 
1.15-million new cases and 410,000 deaths caused by breast cancer in 2002 
(Parkin et al., 2005).  Incidence of breast cancer is increasing in most countries 
and the increasing rate is much higher in countries where its incidence was 
previously low (Parkin et al., 2005).  It has been known that breast cancer is a 
hormone-dependent disease, and estrogens through an interaction with 
estrogen receptor (ER) drastically enhance the proliferative and metastatic 
activity in breast tumor cells (Berry et al.,2005; Yager, et al., 2006).  However, 
despite the clinical benefit of interruption of the ER function with synthetic 
anti-estrogen drugs such as tamoxifen, the precise mechanism of an 
estrogen/ER signaling pathway in breast cancer progression is not well 
understood.  Therefore, further characterization of the pathophysiologic roles of 
this pathway and development of novel drugs targeting this pathway should be 
eagerly expected to provide a better management to breast cancer patients. 
 Gene-expression profile analysis can generate a considerable amount of 
information for characterizing the nature of individual cancers; such information 
should be applied for extraction of potential molecular targets for improving 
clinical strategies to treat neoplastic diseases (Bange et al., 2001;Petricoin et al., 
2002).  Through the genome-wide expression analysis of a large number of 
microdissected clinical cancer materials we have identified dozens of genes that 
function as oncogenes in the process of development and/or progression of 
breast cancer (Park et al., 2006; Shimo et al., 2007; Lin et al., 2007; Shimo et al., 
2008; Ueki et al., 2008), bladder cancer (Kanehira et al., 2007a; 1 Kanehira et al., 
2007b), synovial sarcomas (Nagayama et al., 2004; Nagayama et al., 2005), 
testicular seminoma (Okada et al., 2004) and renal cell carcinoma (Togashi et al., 
2005; Hirota et al., 2006; Dobashi et al., 2009).  These molecules are 
considered to be good candidates for development of new therapeutic modalities.  
Since cytotoxic anti-cancer drugs often cause severe adverse reactions, it is 
obvious that careful selection of novel target molecules on the basis of 
well-characterized mechanisms of action should be very helpful to develop 
effective anti-cancer drugs with the minimum risk of adverse events.  Toward 
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such goals, we performed expression profile analysis of 81 breast tumors and 29 
normal human tissues by means of a cDNA microarray representing 23,040 
cDNAs or ESTs (Nishidate et al., 2004;Saito-Hisaminato et al., 2002) and 
identified dozens of molecules that were over-expressed in a great majority of 
breast cancers and low or undetectably expressed in normal human organs. 
Among many over-expressed genes in breast cancers, we report in this 
study identification and characterization of a novel gene, Brefeldin A-inhibited 
guanine nucleotide-exchange protein 3 (BIG3), a novel member of the 
BIG1/Sec7p subfamily of ADP ribosylation factor-GTP exchange factors 
(ARF-GEFs), to be a key molecule regulating an estrogen/estrogen receptor 
(ER) signaling pathway in breast cancer.  We also demonstrate an interaction of 
BIG3 with prohibitin 2/repressor of estrogen receptor activity (PHB2/REA) 
protein, and that their interaction can enhance the ERα transcriptional activity.  
Our findings imply BIG3 to be a promising target for development of novel 
anti-cancer drugs for breast cancer.  
 
Results 
 
Overexpression of BIG3 in breast cancer cells 
To elucidate the mechanism of breast carcinogenesis and identify molecules that 
could be applicable as targets for development of novel therapeutic drugs, we 
previously performed genome-wide gene-expression profile analysis of 81 
breast cancers using cDNA microarray representing 23,040 cDNAs (Nishidate et 
al., 2004).  Among the transactivated genes, we in this study focused on 
Brefeldin A-inhibited guanine nucleotide-exchange protein 3 (BIG3).  We 
confirmed its upregulation in 9 of 12 clinical breast cancer specimens, compared 
with normal breast ductal cells or with whole mammary gland by 
semiquantitative RT-PCR (Figure 1a).  Subsequent northern-blot analysis 
confirmed overexpression of its 15-kb transcript in breast cancer cell lines 
(Supplementary Figure 1).  On the other hand, BIG3 expression was hardly 
detectable in any of normal human organs except the brain (data not shown) as 
concordant to the results of cDNA microarray analysis.   
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 Since the assembled cDNA sequence of BIG3 (LOC202451; 3348bp) in 
the NCBI database was much smaller than the 15-kb transcript indicated by 
northern-blot analysis, we performed the exon-connection and 5’ RACE 
experiments, and obtained the full-length cDNA sequences of BIG3 consisting of 
14,763 nucleotides (Genebank accession; AB252196) encoding a protein of 
2,177 amino acids.  The BIG3 gene consists of 34 exons, spanning an 
approximately 183-kb genomic region on the chromosomal band 6q23.3.  The 
simple modular architecture research tool (SMART) program predicted a 
presence of a Sec7 domain (586-798 amino-acids), that might be required for 
the protein transport through the Golgi apparatus, in the BIG3 protein (Chardin et 
al., 1996; Jackson et al., 2000; Cox et al., 2004; Casanova et al., 2007). 
 To investigate the biological function of the BIG3 protein, we first 
generated an anti-BIG3 polyclonal antibody and found it to recognize the 
endogenous BIG3 protein of approximately 250 kDa in a breast cancer cell line, 
SK-BR-3, as well as exogenously-expressed BIG3 in COS7 cells without any 
cross-reactivity to other proteins (Supplementary Figure. 2a).  We further 
investigated endogenous expression of BIG3 protein in cell lysates from 13 
breast cancer cell lines by western blot analysis and found that six of them 
(MDA-MB-453, SK-BR-3, ZR-75-1, BT-483, HCC1500 and MCF-7) expressed a 
high level of BIG3 protein, two (T47D and BT-20) expressed it at a low level, and 
no expression was observed in the remaining five cell lines (MDA-MB-231, 
HCC1395, BT-549, HCC1143 and HCC1937) (Figure 1b). Subsequent 
immunohistochemical analysis using anti-BIG antibody showed its strong 
staining in the cytoplasm of two different histological subtypes of breast cancer, 
the papillotubular carcinoma and the solid-tubular carcinoma (Figure 1c), while 
any staining was detected neither in the normal breast tissue (Figure. 1d) nor in 
heart, lung and liver (Supplementary Figure 2b) in concordance with the results 
of northern-blot analysis. 
 
Effect of BIG3 on cell growth 
To ascertain a possible role of BIG3 in mammary carcinogenesis, we knocked 
down the expression of endogenous BIG3 in breast cancer cell lines, SK-BR-3 
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and BT-474, which expressed a high-level of BIG3, using a mammalian 
vector-based RNA interference technique. Introduction of either of two 
BIG3-specific siRNA constructs (si-#2 and si-#3) significantly suppressed the 
BIG3 mRNA expression, compared with a control siRNA construct, si-mock or 
si-#1 (Figure 2a, b; left panels).  In concordance with the knockdown effect, 
MTT (Figure 2a, b; middle panels) and colony formation assays (Figure. 2a, b; 
right panels) revealed significant growth-suppressive effects by si#2 and si#3, 
but not significant by si#1 (mean absorbance of MTT assays in SK-BR-3 cells 
transfected with siBIG3 (si#1, si#2 and si#3) versus si-mock: si#1 versus 
si-mock, mean = 1.90 versus 2.39, difference = -0.49, 95% CI = -0.98 to -0.009, 
P = 0.053; si#2 versus si-mock, mean = 0.48 versus 2.39, difference = -1.90, 
95% CI = -2.44 to -1.37, P = 0.003; si#3 versus si-mock, mean = 0.94 versus 
2.39, difference= -1.44, 95% CI = -1.95 to -0.93, P = 0.005; mean absorbance of 
MTT assays in BT-474 cells transfected with siBIG3 (si#1, si#2 and si#3) versus 
si-mock: si#1 versus si-mock, mean = 2.23 versus 2.41, difference = -0.18, 95% 
CI = -0.72 to -0.36, P = 0.30; si#2 versus si-mock, mean = 0.34 versus 2.41, 
difference= -2.07, 95% CI = -2.63 to -1.51, P = 0.004; si#3 versus si-mock, mean 
= 0.43 versus 2.41, difference= -1.98, 95% CI = -2.54 to -1.42, P = 0.004).  We 
also generated siRNA that contained a 3-base substitution in si#3 sequence  
(mismatch si#3), and found no suppressive effect on the expression of BIG3 or 
on cell growth of SK-BR-3 (Supplementary Figure 3) or BT-474 cells (mean 
absorbance of MTT assays in BT-474 cells transfected with mismatch-siBIG3 
(mismatch si#3) versus si-mock: mismatch si#3 versus si-mock, mean = 2.32 
versus 2.41, difference = -0.09, 95% CI = -0.65 to 0.47, P = 0.57) (Figure 2b).  
These observations suggest that BIG3 has a critical function in the growth of the 
breast cancer cells.   
 
Identification of PHB2/REA as an interacting protein of BIG3 
Since the biological functions of BIG3 are totally unknown, we searched for a 
protein(s) interacting with BIG3 by immunoprecipitation and mass spectrometry 
analyses. Lysates of BT-549 cells transfected with a pCAGGSnH3F-BIG3 vector 
or a pCAGGSnH3F-Mock (mock control) were extracted and 
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immunoprecipitated with anti-Flag M2 monoclonal antibody (see Materials and 
methods).  Protein complexes were silver-stained on SDS-PAGE gels.  An 
approximately 30-kDa protein, which was seen in immunoprecipitates of cell 
lysates transfected with the Flag-tagged BIG3 plasmid but not in those with 
mock control plasmid, was extracted and its peptide sequences were 
determined by mass-spectrometry analysis (data not shown).  This approach 
identified prohibitin 2/repressor of estrogen receptor activity (PHB2/REA) 
(Montano, et al., 1999) as a candidate interacting with BIG3.  To investigate the 
biological significance of their interaction, we constructed plasmids designed to 
express Flag-tagged BIG3 (BIG3-Flag) and HA-tagged PHB2/REA 
(PHB2/REA-HA) (see Materials and methods).  These plasmids were 
co-transfected into COS-7 cells, and then the proteins were immunoprecipitated 
with anti-Flag antibody.  Immunoblot of the precipitates using anti-HA antibody 
indicated that BIG3-Flag was co-precipitated with PHB2/REA-HA (Figure 3a; left 
panel).  Conversely, we performed immunoprecipitation using anti-HA antibody 
and then immunoblot analysis of the precipitates using anti-Flag antibody.  The 
results showed that PHB2/REA-HA was co-precipitated with BIG3-Flag (Figure 
3a; right panel).  We additionally confirmed that BIG3-Flag was co-precipitated 
with endogenous PHB2/REA in SK-BR-3 cells (Figure 3b).   
We subsequently performed immunocytochemical staining analysis with 
anti-PHB2/REA polyclonal antibody using breast cancer cell line, SK-BR-3, (see 
Materials and methods) and observed staining of endogenous PHB2/REA 
mainly as speckled pattern in cytoplasm in most of the breast cancer cells 
(Figure 3c, middle panel).  In a small subset of the cells, its staining was 
observed in both cytoplasm and nucleus (Figure 3c, right panel; arrows).  Since 
PHB2/REA was reported to selectively repress the transcriptional activity of ERα 
through its interaction with ERα in the nucleus (Montano, et al., 1999; 
Delage-Mourroux et al., 2000; Kasashima et al., 2006), we investigated a 
possibility of a direct interaction between BIG3 and ERα, but failed to indicate 
their interaction (data not shown). 
 
Inhibition of nuclear translocation of PHB2/REA by BIG3 
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Since PHB2/REA was shown to be localized mainly at cytoplasm and be 
translocated to the nucleus in ERα-positive cells (Montano, et al., 1999; 
Delage-Mourroux et al., 2000; Kasashima et al., 2006), we hypothesized that 
BIG3 might interact with PHB2/REA and interfere its nuclear translocation.  
Therefore, we performed immunocytochemical staining to examine the 
subcellular distribution of PHB2/REA protein in a presence or an absence of 
BIG3.  Figure 4a showed that endogenous PHB2/REA was also localized in 
cytoplasm of MCF-7 cells, in which BIG3 protein was overexpressed, with or 
without treatment of E2.  Moreover, we confirmed that endogenous PHB2/REA 
was translocated into the nucleus of T47D cells, in which BIG3 was expressed at 
a very low level (Figure 4b, left panels), after E2 treatment.  On the other hand, 
PHB2/REA remained in the cytoplasm even with E2 treatment when BIG3 was 
exogenously introduced into T47D cells (Figure 4b, right panels).  These 
findings suggest that BIG3 interacted with PHB2/REA and interfered its nuclear 
translocation. 
 Furthermore, we investigated the subcellular localization of endogenous 
PHB2/REA in MCF-7 cells in which endogenous BIG3 expression was knocked 
down using the siRNA oligonucleotide of BIG3 (si-BIG3).  The significant 
knockdown of BIG3 expression was observed in si-BIG3-transfected MCF-7 
cells, but not in si-EGFP-transfected cells as a control (Figure 4c).  PHB2/REA 
was localized in the nucleus at 48 h after the E2 treatment, but was present in 
the cytoplasm in those treated with si-EGFP (Figure 4d).  We also confirmed 
that the knockdown of BIG3 expression also led to the nuclear-translocation of 
PHB2/REA in ZR-75-1 cells, which expressed a high-level of BIG3 
(Supplementary Figure 4).  These data further support that BIG3 trapped 
PHB2/REA in the cytoplasm, and resulted in inhibition of its nuclear translocation 
and the interaction with ERα. 
 
BIG3 up-regulates ERα transcriptional activity though its interaction with 
PHB2/REA 
To examine whether BIG3 protein could enhance the ERα transcriptional activity 
in breast cancer cells, we transfected with estrogen-responsive reporter gene 
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(pERE-TA-SEAP) vector followed by the transfection with either of the si-BIG3 or 
si-EGFP into MCF-7 cells, and then performed reporter assay (see Materials and 
methods).  We confirmed the knockdown of BIG3 expression by western-blot 
analysis (Figure 5a), and found that the depletion of BIG3 expression caused the 
significant decrease of ERα transcriptional activity in MCF-7 cells (mean relative 
ERα transcriptional activity in MCF-7 cells transfected si-BIG3 after E2 
stimulation versus MCF-7 cells transfected with si-EGFP after E2 stimulation; 
0.65 versus 0.99, difference = -0.35. 95% CI =-0.38 to -0.31, P = 0.0006; mean 
relative ERα transcriptional activity in MCF-7 cells transfected with si-BIG3 
without E2 stimulation versus MCF-7 cells transfected si-EGFP without E2 
stimulation; 0.93 versus 0.94, difference = -0.02. 95% CI = -0.27 to 0.23, P = 
0.57) (Figure 5b).  These findings suggest that the presence of BIG3 protein is 
likely to enhance the ERα transcriptional activity though inhibition of nuclear 
translocation PHB2/REA in breast cancer cells. 
 
 
Discussion 
Identification and characterization of cancer-related genes and their 
products have contributed to the development of molecular-targeting drugs for 
cancer therapy in the last two decades.  However, the proportion of patients 
having benefit by presently available treatments is still limited (Berry et al.,2005; 
Yager, et al., 2006).  Hence, it is urgent to further develop new anticancer 
agents that are highly specific to malignant cells, with minimal or no adverse 
reactions.  Through the precise expression profile analysis of breast cancer, we 
identified BIG3 to be significantly overexpressed in the great majority of breast 
cancer cases and breast cancer cell lines.  The immunohistochemical analysis 
also supported the high level of endogenous BIG3 protein in breast cancer cells 
in concordance with the results of northern blot analysis.  Knockdown of the 
endogenous BIG3 expression resulted in remarkable growth suppression of 
breast cancer cells.  These results implied that BIG3 could serve as a valuable 
target for development of anti-cancer agents for breast cancer. 
ADP ribosylation factors (Arfs) are approximately 20-kDa GTPases that 
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have key roles in the regulation of protein trafficking and guanine-nucleotide 
exchange in eukaryotic cells (Jackson et al., 2000; Cox et al., 2004; Casanova et 
al., 2007).  The Arfs require accessory proteins to facilitate nucleotide 
exchange [GTP exchange factors (GEFs)] and GTP hydrolysis [GTPase 
activating proteins (GAPs)].  The mammalian Arfs are divided into three classes 
I-III; class-I Arf is involved in transport though the exocytic pathway and class-III 
is implicated in endocytosis and in actin dynamics at the plasma membrane.  
Little is unknown about the roles of class-II Arf (Jackson et al., 2000; Cox et al., 
2004; Casanova et al., 2007).  All of Arf-GEFs identified to date are 
characterized by a central catalytic domain of approximately 200 amino acids 
referred to as the Sec7 domain that is sufficient for GEF activity (Jones et al., 
1999; Jackson et al., 2000; Cox et al., 2004; Casanova et al., 2007).  Brefeldin 
A-inhibited guanine nucleotide-exchange proteins 1 and 2 (BIG1 and BIG2) 
contain highly conserved sec7 domains that catalyze replacement of ARF-bound 
GDP by GTP to initiate membrane vesicle formation (Cox et al., 2004; Casanova 
et al., 2007).  Although it was considered to belong to the sec7/Arfs protein 
family, BIG3 contains a single highly-conserved Sec7 domain and shares 
partially the only 25% identity in amino acid sequences with BIG1 and BIG2 
proteins, that were initially isolated from bovine brain cytosol on the basis of their 
brefeldin A-sensitive activation of calss-I Arfs (Cox et al., 2004; Yamaji et al., 
2000).  Therefore, to elucidate the biological significance of BIG3 in breast 
cancer cells, we screened a protein(s) interacting with BIG3 and identified 
PHB2/REA, which is known to be an estrogen receptor α (ERα)-selective 
coregulator (Montano, et al., 1999; Delage-Mourroux et al., 2000; Kasashima et 
al., 2006), as a candidate.  We demonstrated their in vivo interaction and 
co-localization at the cytoplasm of breast cancer cells.  We further confirmed 
that endogenous PHB2/REA was localized in cytoplasm under the presence of 
BIG3 regardless with or without stimulation of E2, but it translocated to the 
nucleus, and repressed the transcriptional activity under the absence of BIG3 
protein (Figure 4 and 5).  Moreover, all of ERα-positive breast cancer cells we 
examined showed the overexpression of PHB2/REA (data not shown).  
Therefore, it suggests the possibility that PHB2/REA protein may function as the 
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negative-feedback mechanism to suppress the activated ER signaling.  Taken 
together, these results imply the constitutive activation of ER signaling pathway 
by overexpression of BIG3 in breast cancer in vivo (Figure 6).   Additionally, 
these findings may explain why there is no apparent correlation between 
PHB2/REA expression and ERα inactivation in breast cancer cases.  
Furthermore, although further analysis of the BIG3 function by evaluation of 
activation of ER-downstream genes will be necessary, our data should contribute 
to more profound understanding of the estrogen/ ER signaling pathway in breast 
cancer carcinogenesis. 
 Our findings demonstrated for the first time that endogenous PHB2/REA 
was trapped in the cytoplasm under the presence of BIG3 regardless with or 
without stimulation of E2, while it was translocated to the nucleus and repressed 
the transcriptional activity without a high level of BIG3 protein in the cytoplasm. 
The overexpression of BIG3 might play an important role in determining the 
sensitivity of estrogen-target drugs for breast cancer cells.  Since inhibition of 
the interaction between BIG3 and PHB2/REA may lead to rescue the 
nuclear-translocation of PHB2/REA protein in ER-dependent breast cancer cells, 
the inhibitor for their interaction would be a possible valuable target to develop 
agents against breast cancer.  Our data should contribute to a better 
understanding of breast carcinogenesis, and imply that BIG3 is a promising 
molecular target for breast cancer treatment. 
 
Materials and Methods 
 
Cell lines and clinical samples 
Human breast cancer cell lines, HCC1937, MCF-7, MDA-MB-231, SK-BR-3, 
T47D, BT-549, HCC1395, MDA-MB-157, BT-20, MDA-MB-453, ZR-75-1, BT-483, 
BT-474, HCC1143, HCC1500, HCC1599 and OCUB-F, as well as African green 
monkey SV40-transfected kidney fibroblast cell line, COS-7 and mouse 
fibroblast cell line, NIH3T3 were purchased from American Type Culture 
Collection (ATCC, Rockville, MD), and cultured under their respective depositors’ 
recommendations.  HBC4 and HBC5 were kind gifts from Dr. Takao Yamori of 
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Division of Molecular Pharmacology, Cancer Chemotherapy Center, Japanese 
Foundation for Cancer Research.  All cells were cultured in appropriate media; 
i.e. RPMI-1640 (Sigma-Aldrich, St. Louis, MO) for HBC4, HBC5, HCC1937, 
T47D, BT-549, HCC1395, ZR-75-1, BT-483, HCC1143, HCC1500 and HCC1599 
(with 2mM L-glutamine); Dulbecco’s modified Eagle’s medium (Sigma-Aldrich) 
for BT-474, OCUB-F, COS-7 and NIH3T3; EMEM (Sigma-Aldrich) for MCF-7 and 
BT-20 (with 10µg/ml Insulin); McCoy (Sigma-Aldrich) for SK-BR-3 (with 1.5mM 
L-glutamine); L-15 (Roche, Basel, Switzerland) for MDA-MB-231, MDA-MB-157 
and MDA-MB-453.  Each medium was supplemented with 10% fetal bovine 
serum (FBS; Cansera International, Ontario, Canada) and 1% 
antibiotic/antimycotic solution (Sigma-Aldrich).  MDA-MB-231, MDA-MB-157 
and MDA-MB-453 cell lines were maintained at 37oC in atmosphere of 
humidified air without CO2, and other cell lines were maintained at 37oC in 
atmosphere of humidified air with 5% CO2.  Tissue samples from 
surgically-resected breast cancers and their corresponding clinical information 
were obtained from Department of Breast Surgery, Cancer Institute Hospital, 
Tokyo after obtaining written informed consent. 
 
Semiquantitative reverse transcription-PCR analysis 
Microdissection of breast cancer cells was performed as described previously 
(Nishidate et al; 2004).  Total RNAs were extracted from each of microdissected 
breast cancer clinical samples, microdissected normal breast ductal cells and 
breast cancer cell lines using RNeasy Micro Kits (Qiagen, Valencia, CA), and 
purchased polyA (+) RNAs isolated from mammary gland, heart, lung, liver, 
kidney and bone marrow from Takara Clontech (Kyoto, Japan).  Subsequently, 
T7-based amplification and reverse transcription were carried out as described 
previously (Nishidate et al; 2004).  Three-microgram aliquots of each amplified 
RNA were reversely transcribed for single-stranded cDNAs using oligo (dT)12-18 
primer and Superscript II (Invitrogen, Carlsbad, CA) at 42oC for 60 min.  We 
prepared appropriate dilutions of each single-stranded cDNA for subsequent 
PCR by monitoring β2-microgloblin (β2-MG) as a quantitative internal control.  
PCR amplification was performed using EX-taq polymerase (Takara) and the 
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cDNAs as templates with the following primers: 
5’-CTTGACAAGGCCTTTGGAGT-3’ and 5’-CAATATGCTTTTCCCGCTTT-3’ for 
BIG3; 5’-AACTTAGAGGTGGG AGCAG-3’ and 5’-CACAACCATGC 
CTTACTTTATC-3’ for β2-MG.  PCRs were optimized for the number of cycles 
to ensure product intensity within the logarithmic phase of amplification.  The 
PCR conditions were 94 oC for 30 sec, 58 oC for 30 sec and 72 oC for 30 sec for 
21 cycles for β2-MG and 28 cycles for BIG3.  The PCR products were resolved 
by electrophoresis on 2.0% ethidium bromide-stained agarose gels, and band 
intensity was quantified with the use of NIH Image analysis software 
(http://rsb.info.nih.gov/nih-image/). 
 
5’ rapid amplification of cDNA ends (5’ RACE) 
5’ RACE experiments were carried out using SMART RACE cDNA amplification 
kit (Takara Clontech) according to the manufacturer’s instructions.  For the 
amplification of the 5’ part of BIG3 cDNA, a gene-specific primer 
(5’-GCCTCCTTCTGCAGCTTCCTCAGGATTT-3’) and a universal primer 
mixture supplied in the kit were used.  The cDNA template was synthesized 
from mRNA extracted and purified from MDA-MB-453 breast cancer cells, using 
Superscript III Reverse Transcriptase (Invitrogen).  The PCR products were 
cloned using TA cloning kit (Invitrogen) and sequences were determined by DNA 
sequencing (ABI3700; PE Applied Biosystems, Foster, CA). 
 
Construction of BIG3 Expression Vectors 
To construct BIG3 expression vector, the entire coding sequence was amplified 
by PCR using KOD-Plus DNA polymerase (TOYOBO, Osaka, Japan).  Primer 
sets were 5'-CGGAATTCATGGAAGAAATCCTGAGGAAGC-3’ and 
5’-ATAGTTTAGCGGCCGCACAATGATGTCATAGACACGG-3' (underlines 
indicate recognition sites of restriction enzymes).  The PCR product was 
inserted into the EcoRI and NheI sites of pCAGGSnH3F expression vector in 
frame with a hemagglutinin (HA) tag at the N-terminus and a Flag-tag at the 
C-terminus.  DNA sequences of the construct were confirmed by DNA 
Jung-Won Kim, et al. 
 14
sequencing (ABI3700; PE Applied Biosystems).   
 
Generation of anti-BIG3 specific polyclonal antibody 
Plasmids designed to express two fragments of BIG3 (codons 459-572 and 
799-1200) using pET21a (+) vector in frame with a T7 tag at the N-terminus and 
a histidine (His) tag at the C-terminus (Novagen, Madison, WI), respectively.  
The two recombinant peptides were expressed in Escherichia coli, BL21 
codon-plus strain (Stratagene, La Jolla, CA), respectively, and purified using 
Ni-NTA resin agarose (Qiagen) according to the supplier’s protocols.  The 
purified recombinant proteins were mixed together and then used for 
immunization of rabbits (Medical and Biological Laboratories, Nagoya, Japan).  
The immune sera were subsequently purified on antigen affinity columns using 
Affigel 15 gel (Bio-Rad Laboratories, Hercules, CA) according to supplier’s 
instructions.  We confirmed that this antibody could specifically recognize 
endogenous BIG3 protein in breast cancer cell line, SK-BR-3 cells.  An 
affinity-purified anti-BIG3 antibody was used for western blot, 
immunocytochemical and immunohistochemical analyses as described below. 
 
Western blot analysis 
To examine the expression of endogenous BIG3 protein in breast cancer cell 
lines (MDA-MB-231, MDA-MB-453, SK-BR-3, T47D, ZR-75-1, BT-483, 
HCC1395, BT-20, BT-549, HCC1143, HCC1500, HCC1937 and MCF-7), cells 
were lysed with lysis buffer (50mM Tris-HCl, pH 8.0, 150mM NaCl, 0.1% NP-40 
and 0.5% CHAPS) including 0.1% protease inhibitor cocktail III (Calbiochem, 
San Diego, CA).  After homogenization, cell lysates were incubated on ice for 
30 min and centrifuged at 14,000 rpm for 15 min to separate only supernatant 
from cell debris.  The amount of total protein was measured by protein assay kit 
(Bio-Rad), and then the proteins were mixed with SDS-sample buffer and boiled 
for 5 min before loading at 7.5% SDS-PAGE gel.  After electrophoresis, the 
proteins were blotted onto nitrocellulose membrane (GE Healthcare, 
Buckinghamshire, United Kingdom).  After blocking with 4% BlockAce blocking 
solution (Dainippon Pharmaceutical. Co., Ltd, Osaka, Japan) for 1 h, 
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membranes were incubated with purified anti-BIG3 polyclonal antibody for 
another 1 h to detect endogenous BIG3 protein.  Finally, the membrane was 
incubated with HRP conjugated secondary antibody (1:10000 dilution; GE 
Healthcare) for 1 h, and protein bands were visualized by ECL detection reagent 
(GE Healthcare).  
 
Immunocytochemical staining 
To examine the subcellular localization of endogenous BIG3 and PHB2/REA 
proteins in breast cancer cells, MCF-7 or T47D cells were seeded at 1 x 105 cells 
per well (Lab-Tek II Chamber Slide System; Nalgen Nunc International, 
Naperville, IL) under estrogen-free conditions as describe below.  Cells were 
then fixed with Phosphate Buffered Saline (PBS; Sigma-Aldrich) containing 4% 
paraformaldehyde at 4oC for 30 min and rendered permeable with PBS 
containing 0.1% Triton X-100 at 4 oC for 2 min.  Subsequently, the cells were 
covered with 3% BSA in PBS for 1 h to block non-specific hybridization followed 
by incubation with anti-BIG3 polyclonal antibody or anti-PHB2/REA polyclonal 
antibody diluted at 1:500 or 1:500 for another 1 h.  After washing with PBS (-), 
cells were stained by Alexa 488-conjugated anti-rabbit secondary antibody 
(Molecular Probe, Eugene, OR) diluted at 1:1000 for 1 h.  Nuclei were 
counter-stained with 4’, 6’-diamidine-2’-phenylindole dihydrochloride (DAPI).  
Fluorescent images were obtained under TCS SP2 AOBS microscope (Leica, 
Tokyo, Japan). 
 
Immunohistochemical staining 
To examine the expression of BIG3 protein in breast cancer and normal tissues, 
we prepared slides of 4μm sections of paraffin-embedded breast cancer tissue 
(sample No. 240, 241, 238, 242 and 290), normal mammary tissue (sample No. 
453) and other commercially available normal human tissues (lung, heart, and 
liver) (BioChain, Hayward, CA).  Specimens were deparaffinized by the 
treatment with xylene and ethanol, then processed for antigen retrieval by 
autoclave at 108oC for 15 min in antigen retrieval solution, high pH (DAKO 
Cytomation, Glostrup, Denmark) and treated with peroxidase blocking reagent 
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(DAKO Cytomation) for 1 h.  Tissue sections were incubated with anti-BIG3 
polyclonal antibody diluted at 1:150 for 1 h and followed by horseradish 
peroxidase-conjugated secondary antibody (DAKO Cytomation) for 30 min.  
Specific immunostaining was visualized with peroxidase substrate (3, 
3’-diaminobenzidine tetrahydrochloride) (DAKO liquid DAB+ chromogen; DAKO 
Cytomation).  Finally, tissue specimens were stained with hematoxylin to 
discriminate nucleus from cytoplasm. 
 
Gene-silencing effect by small interfering RNA 
We had established a vector-based RNAi (RNA interference) expression system 
using psiU6BX3.0 siRNA expression vector as described previously (Shimokawa 
et al; 2003).  The siRNA expression vectors against BIG3 (psiU6BX3.0-BIG3) 
were prepared by cloning of double-stranded oligonucleotides into the BbsI site 
in the psiU6BX3.0 vector.   The target sequences of synthetic oligonucleotides 
for siRNAs were as follows; 5'-AAGGTCCTATGGATCTAGGTA-3' for si-#1, 
5'-AAGAAAGCA TCGCAGTCTCAG-3' for si-#2, 5'-AAGATGCGTTCT 
CTGCCACAC-3' for si-#3, 5'-AATATTCGATCTCTGCCACAC-3' for si-m#3 (bold 
letters indicate mismatched sequence in si-#3).  All of the constructs were 
confirmed by DNA sequencing (ABI3700; PE Applied Biosystems).  Human 
breast cancer cell lines, SK-BR-3 and BT-474, were plated onto 10 cm dishes (1 
x 106 cells/dish) and transfected with 8µg each of psiU6BX3.0-Mock (without 
insertion) and psiU6BX3.0-BIG3 (si-#1, si-#2, si-#3 and si-m#3 including 
three-base substitutions in #3) using FuGENE6 transfection reagent (Roche) 
according to the manufacturer’s instructions.  After 24 h of transfection, cells 
were re-seeded for colony formation assay (1 x 106 cells/10 cm dish), RT-PCR (1 
x 106 cells/10 cm dish) and 3-(4,5-dimethylthiazol-2-yl)- 2,5-diphenyltetrazolium 
bromide (MTT) assay (2 x 105 cells/well).  We selected psiU6BX3.0-introduced 
SK-BR-3 or BT-474 cells with culture medium containing 0.2mg/ml or 1.0mg/ml 
of neomycin (geneticin; Invitrogen), respectively.  We changed culture medium 
twice a week.  Total RNAs were extracted from the cells after 3-day incubation 
with neomycin, and then the knockdown effect of siRNAs was examined by 
semi-quantitative RT-PCR using specific primer sets; 
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5’-GCCCTTGAAGCCAATATTCC-3’ and 5’-AGATGGTTTCAGTGGGCTTG-3’ for 
BIG3; 5’-AACTTAGAGGTGGGAGCAG-3’ and 
5’-CACAACCATGCCTTACTTTATC-3’ for β2-MG as an internal control.  
SK-BR-3 or BT-474 cells expressing siRNA were grown for 4 weeks in selective 
media containing 0.2 mg/ml or 1.0 mg/ml of neomycin, and then fixed with 4% 
paraformaldehyde at 4oC for 30 min before staining with Giemsa’s solution 
(Merck, Whitehouse Station, NJ) to assess the colony number.  To quantify cell 
viability, MTT assays were performed with cell counting kit-8 (Wako, Osaka, 
Japan) according to manufacturer’s recommendations.  Absorbance at 570 nm 
wavelengths was measured with a Microplate Reader 550 (Bio-Rad).  These 
experiments were performed in triplicate. 
 Furthermore, we used siRNA oligonucleotides (Sigma Aldrich Japan KK, 
Tokyo, Japan) due to its high transfection efficiency to further verify the 
subcellular localization of PHB2/REA protein in cells which BIG3 gene was 
knocked-down by siRNA.  The sequences targeting BIG3 (siBIG3) or EGFP 
(siEGFP) were as follows: si-BIG3; 5’-GAUGCGUUCUCUGCCACACTT-3’, 
siEGFP (control); 5’-GCAGCACGACUUCUUCAAG-3’.  MCF-7 or ZR-75-1 (2.5 
X105 cells in 10cm dish) cells were transfected with those siRNAs using 
Lipofectamin RNAiMAX (Invitrogen, Carlsbad, CA) in OptiMEM (Invitrogen) 
medium according to the instructions of manufacture.  After 24 h of the 
transfection, the cells were treated with 1μM of E2 (17β-estradiol; Sigma-Aldrich), 
and then were applied for immunocytochemical and western blot analyses using 
anti-PHB2/REA polyclonal antibody (Abcam, Cambridge, UK), anti-ERα 
monoclonal antibody (LAB VISION, Fremount, CA) and anti-BIG3 polyclonal 
antibody according to the method described in the western blot and 
immunocytochemical analyses sections.  Fluorescent images were obtained 
under TCS SP2 AOBS microscope (Leica). 
 
Immunoprecipitation and mass spectrometry 
To identify an interacting protein(s) with BIG3 protein, BT-549 cells were plated 
onto 15-cm dishes (1 x 107 cells/dish) and transfected with 20µg of 
pCAGGSnH3F-Mock (without insertion) or pCAGGSnH3F-BIG3 using 
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FuGENE6 reagent (Roche) according to the manufacturer’s instructions.  After 
48-h incubation, the cells were lysed with 0.1% NP-40 lysis buffer as described 
in western blot analysis section.  The cell lysates were pre-cleaned with normal 
mouse IgG and rec-Protein G Sepharose 4B (Zymed, San Francisco, CA) at 4°C 
for 1 h.  Subsequently, the lysates were incubated with anti-Flag M2 agarose 
(Sigma-Aldrich) at 4oC for overnight.  After washing five times with lysis buffer, 
proteins on beads were eluted with SDS-sample buffer by boiling for 5 min.  
The eluted protein samples were separated by SDS-PAGE using NuPAGE 
4-12% Bis-Tris gel (Invitrogen).  Proteins in polyacrylamide gel were silver 
stained by SilverQuest Silver Staining Kit (Invitrogen) according to the 
manufacturer’s instructions.  Bands that were specifically observed in the 
BIG3-transfected lane were excised with a clean, sharp scalpel and the 
extracted proteins were applied for PMF (Peptide Mass Fingerprint) analysis 
using MALDI TOF-MS (Shimadzu Biotech, Tsukuba, Japan). 
 
Co-immunoprecipitation assay 
For co-immunoprecipitation assay, plasmids designed to express the entire 
coding sequence of PHB2/REA were constructed using the following primer set; 
5'-CGGAATTCCAGACCGTGCATCATGGCCCAGAACTTGAAGGA-3’ and 
5'-CCGCTCGAGTTTCTTACCCTTGATGAGGCTGT-3’ (underlines indicate the 
recognition sites of restriction enzymes), and inserted in frame into the EcoRI 
and XhoI sites of pCAGGSnHC expression vector with an HA tag at the 
C-terminus (pCAGGSnHC-PHB2/REA).  BIG3 expression vector 
(pCAGGSnH3F-BIG3) was subcloned into pCAGGSn3FC expression vector in 
frame with a Flag-tag at the C-terminus (pCAGGSn3FC-BIG3).  COS-7 cells 
were transiently transfected with either or both of pCAGGSn3FC-BIG3 and 
pCAGGSnHC-PHB2/REA.  After 48 h of the transfection, the cells were lysed 
with 0.1% NP-40 lysis buffer as described in western blot analysis section.  The 
cell lysates were pre-cleaned at 4°C for 1 h, and subsequently incubated with 
anti-Flag M2 agarose (Sigma-Aldrich) or monoclonal anti-HA agarose conjugate 
(Sigma-Aldrich) at 4°C for overnight.  After washing with lysis buffer, 
co-precipitated proteins were separated by SDS-PAGE.  Finally, we performed 
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western blot analysis using anti-HA high affinity (3F10) rat monoclonal antibody 
(Roche) or anti-Flag M2 monoclonal antibody (Sigma-Aldrich) to detect the 
exogenously expressed PHB2/REA or BIG3 protein, respectively. 
 
Cell culture, transfection under estrogen-Free conditions 
For immunocytochemical staining, T47D or MCF-7 cells were cultured with the 
following media; phenol red-free RPMI-1640 (Invitrogen), supplemented with 
10% FBS and 1% antibiotic/antimycotic solution (Sigma-Aldrich) filtered with 
minisart-plus (Sartorius AG, Goettingen, Germany).  The cells were maintained 
at 37°C in atmosphere of humidified air with 5% CO2.  Transfection with BIG3 
(pCAGGSnH3F-BIG3) expression vector was performed using FuGENE6 
transfection reagent (Roche) and phenol red-free Opti-MEM (Invitrogen), 
according to the manufacturer’s instructions.  After 24 h of the transfection, the 
media were exchanged with phenol red-free Opti-MEM containing 1μM of E2 
(17β-estradiol; Sigma-Aldrich) and then incubated for 24 h.  
Immunocytochemical staining was performed using anti-Flag rabbit polyclonal 
antibody (Sigma-Aldrich) diluted at 1:500, and Alexa 594-conjugated anti-rabbit 
secondary antibody (Molecular Probe, Eugene, OR) diluted at 1:1000. 
 
Estrogen responsive element (ERE) reporter gene assays 
An ERE reporter gene construct and fluorescent SEAP assay kit were 
purchased from Clontech (Takara, Kyoto, Japan).  MCF-7 cells were 
transfected with siRNA-oligonucleotides of BIG3 (si-BIG3) or EGFP (si-EGFP; 
control) using Lipofectamin RNAiMAX (Invitrogen) in phenol red-free OptiMEM 
(Invitrogen) medium.  After 24 h of the transfection, the cells were washed with 
PBS (-) at three times, and were transfected with estrogen-responsive reporter 
gene (pERE-TA-SEAP) vector using phenol red-free OptiMEM for 12 h.  
Subsequently, 1μM of E2 was treated for 48 h for SEAP assay and western blot 
analysis, respectively.  The SEAP reporter assay was performed using SEAP 
assay kit (Takara, Clontech) according to the supplier’s recommendations.   
 
Statistical analysis 
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All experimental data are summarized as the mean value with 95% confidence 
intervals (CIs).  All statistical analyses were performed using the two-sample t 
test with Welch’s correction, and were two-side.  Differences were considered 
to be statistically significant at a value of P less than 0.05. 
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Figure legends  
Figure 1 Expression profiles of BIG3.  (a) Expression of BIG3 in 12 clinical 
breast cancer samples (4T, 5T, 110T, 214T, 138T, 327T, 341T, 411T, 631T, 758T, 
624T and 869T) and normal human tissues (normal duct; microdissected normal 
mammary ductal cells, mammary gland, lung, heart, liver, kidney and bone 
marrow) examined by semi-quantitative RT-PCR. β2-MG served as the quantity 
control.  (b) Expression of endogenous BIG3 protein in 13 breast cancer cell 
lines examined by western blot analysis using an affinity-purified anti-BIG3 
polyclonal antibody. ACTB (beta-actin) served as a loading control.  (c, d) The 
results of immunohistochemistry of breast cancer and normal breast tissue 
sections.  The endogenous BIG3 protein was stained with anti-BIG3 polyclonal 
antibody.  The expression was hardly detectable in normal breast tissues 
(Sample No. 453) as shown in (d), but cancer cells were stained mainly at 
cytoplasm in all of cancer tissues investigated, including papillo-tubular (Sample 
nos. 240 and 241) and solid tubular carcinomas (Sample Nos. 238, 242 and 
290) as shown in (c).  Representative Figures are from microscopic observation 
with original magnification of x100.   
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Figure 2 Effect of BIG3 on cell growth.  (a) Semiquantitative RT-PCR showing 
the suppression of endogenous expression of BIG3 in SK-BR-3 breast cancer 
cells (si-#2, si-#3) at 3 days after neomycin selection (left panels).  β2-MG 
served as the quantity control.  MTT and colony formation assays showed a 
significant decrease in the number of colonies by knockdown of BIG3 in 
SK-BR-3 cells (middle and right panels).  The value shown in MTT assay are 
the means and upper 95% confidence intervals for three independent 
experiments performed in triplicate.  Error bars are 95% CIs.  *P=0.003; **P= 
0.005.  (b) Semiquantitative RT-PCR demonstrates the suppression of 
endogenous expression of BIG3 in BT-474 breast cancer cells by BIG3-specific 
siRNAs (si-#2, si-#3) (left panels), while knockdown effect of mismatch siRNA 
(mismatch #3) is not observed (mis-match si#3) (left panels).  MTT and colony 
formation assay showed a decrease in the number of colonies by knockdown of 
BIG3 in BT-474 cells (middle and right panel).  The value shown in MTT assay 
are the means and upper 95% confidence intervals for three independent 
experiments performed in triplicate.  Error bars are 95% CIs.  *P=0.004; **P= 
0.004.   
 
Figure 3 Interaction of BIG3 and PHB2/REA.  (a) Interaction of exogenous 
BIG3 and exogenous PHB2/REA protein. COS-7 cells were transfected with a 
combination of Flag-tagged mock (mock-Flag), Flag-tagged BIG3 (BIG3-Flag), 
HA-tagged mock (mock-HA) and HA-tagged PHB2/REA (PHB2/REA-HA), 
immunoprecipitated with anti-Flag M2 agarose or anti-HA high affinity (3F10) rat 
monoclonal antibody, and immunoblotted with anti-HA high affinity (3F10) rat 
monoclonal antibody (left panels) or anti-Flag M2 monoclonal antibody (right 
panels), respectively.  (b) Confirmation of interaction between exogenous BIG3 
and endogenous PHB2/REA protein.  SK-BR-3 breast cancer cells were 
transfected with the Flag-tagged BIG3 (BIG3-Flag), immunoprecipitated with 
anti-Flag M2 agarose, and immunoblotted with anti-PHB2/REA polyclonal 
antibody. WCL indicates whole cell lysate.  (c) Endogenous expression of 
PHB2/REA in breast cancer cells.  Immunocytochemistry was performed in 
SK-BR-3 breast cancer cells using an anti-PHB2/REA polyclonal antibody 
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(green) and DAPI (blue) to discriminate nucleus. Endogenous PHB2/REA was 
localized mainly in cytoplasm, but the nuclear localization was observed in some 
cells (arrows). 
 
Figure 4 Inhibition of the nuclear translocation of PHB2/REA by overexpression 
of BIG3.  (a) Subcellular localization of PHB2/REA in MCF-7 cells, which 
overexpressed BIG3 protein.  Endogenous PHB2/REA protein was located in 
cytoplasm of MCF-7 cells with or without treatment of E2.  The arrows show 
cytoplasmic PHB2/REA in MCF-7 cells.  (b) Subcellular localization of 
PHB2/REA in T47D cells in which an expression level of BIG3 protein was very 
low (left panels), when BIG3 protein was exogenously expressed.  The arrows 
show endogenous PHB2/REA in nucleus of T47D cells.  T47D cells were 
transfected with Flag-tagged BIG3 (BIG3-Flag; green) and treated with 1μM of 
E2 for 24 h (right panels).  Endogenous PHB2/REA (red) remained in 
cytoplasm in the presence of BIG3 (the right panels; Merge).  The arrows show 
co-localization of endogenous PHB2/REA and exogenous BIG3 in cytoplasm of 
T47D cells.  (c) Expression of BIG3, ERα and PHB2/REA at the protein level in 
MCF-7 cells treated with si-BIG3 oligonucleotide.  After 24 h of the transfection 
with each siRNA oligonucleotide, the cells were treated with E2 for 24, 48 or 72 h, 
and then were analyzed by western blot analysis.  si-EGFP was used as a 
control siRNA.  ACTB served as a loading control for western blot analysis.  
(d) Subcellular localization of endogenous PHB2/REA in BIG3-depleted cells.  
MCF-7 cells were treated with si-BIG3 or si-EGFP.  After 24 h of the siRNA 
treatment, the cells were treated with E2 for 48 h, and then were analyzed by 
immunocytochemical staining. 
 
Figure 5 Regulation of ERα transcriptional activity though its interaction between 
PHB2/REA and BIG3.  (a) Knockdown of BIG3 expression at the protein level in 
the cells treated with si-BIG3.  After 24 h of the transfection with si-BIG3, the 
cells were treated with E2 for 48 h, and then were analyzed by western blot 
analysis.  The si-EGFP was used as a control siRNA.  ACTB served as a 
loading control for western blot analysis.  The arrow indicates the BIG3 protein.  
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(b) SEAP assay to determine the transcriptional activity of ERα in BIG3-depleted 
cells.  MCF-7 cells were transfected with siRNA-oligonucleotides of BIG3 
(si-BIG3) or EGFP (si-EGFP; control).  After 24 h of the transfection, the cells 
were washed with PBS (-) at three times.  Subsequently, the 
estrogen-responsive reporter gene (pERE-TA-SEAP) vector was transfected 
using phenol red-free OptiMEM in MCF-7 cells for 12 h and treated with 1μM of 
E2 for additional 48 h.  The SEAP reporter activity was measured relative to the 
response to E2 in the mock-transfected cells, which was set at 1.0.  The value 
shown in SEAP assay are the means and upper 95% confidence intervals for 
three independent experiments performed in duplicate.  *P=0.0006.   
 
Figure 6 Schematic presentation of up-regulation of ER-signaling pathway by 
BIG3.  In the absence of BIG3, PHB2/REA is translocated to the nucleus, binds 
to ERα, and represses the transcriptional activity of the estradiol (E2)-ligand ERα 
(left panel).  On the other hand, in the presence of BIG3, PHB2/REA binds to 
BIG3 in the cytoplasm and its nuclear translocation is inhibited regardless with or 
without E2 stimulation (right panel), resulting in the constitutive activation of the 
ER signaling. 
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